NASDAQ:JAGXJaguar Health Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Jaguar Health Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.44 +0.00 (+0.55 %) (As of 06/3/2020 04:00 PM ET) Add Compare Share Today's Range$0.43Now: $0.44▼$0.4650-Day Range$0.41MA: $0.48▼$0.6452-Week Range$0.35Now: $0.44▼$17.00Volume4.78 million shsAverage Volume1.22 million shsMarket Capitalization$26.02 millionP/E RatioN/ADividend YieldN/ABeta0.8 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its human health product pipelines include Mytesi, which is Phase II clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, and irritable bowel syndrome - diarrhea predominant diseases; and SB-300, a second-generation anti-secretory agent for multiple indications, including cholera. The company's animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of various forms of diarrhea in dogs; and Equilevia is Jaguar's non-prescription product for total gut health in equine athletes. In addition, the company's products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. is headquartered in San Francisco, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingJaguar Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Jaguar Health has a potential upside of 804.2% from its current price of $0.44.Amount of Analyst CoverageJaguar Health has received no research coverage in the past 90 days. Previous Next 4.4 Community Rank Outperform VotesJaguar Health has received 1,813 “outperform” votes. (Add your “outperform” vote.)Underperform VotesJaguar Health has received 255 “underperform” votes. (Add your “underperform” vote.)Community SentimentJaguar Health has received 87.67% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Jaguar Health and other stocks. Vote “Outperform” if you believe JAGX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe JAGX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldJaguar Health does not currently pay a dividend.Dividend GrowthJaguar Health does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Jaguar Health insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 11.26% of the stock of Jaguar Health is held by insiders.Percentage Held by InstitutionsOnly 0.46% of the stock of Jaguar Health is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Jaguar Health are expected to grow in the coming year, from ($0.69) to $0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jaguar Health is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Jaguar Health is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJaguar Health has a P/B Ratio of 2.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.71 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:JAGX Previous Symbol CUSIPN/A CIK1585608 Webwww.jaguaranimalhealth.com Phone415-371-8300Debt Debt-to-Equity Ratio0.08 Current Ratio0.42 Quick Ratio0.25Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5.78 million Price / Sales4.50 Cash FlowN/A Price / Cash FlowN/A Book Value$0.16 per share Price / Book2.77Profitability EPS (Most Recent Fiscal Year)($6.89) Net Income$-38,540,000.00 Net Margins-755.26% Return on Equity-538.90% Return on Assets-88.17%Miscellaneous Employees40 Outstanding Shares58,814,000Market Cap$26.02 million Next Earnings Date8/12/2020 (Estimated) OptionableNot Optionable NASDAQ:JAGX Rates by TradingView Receive JAGX News and Ratings via Email Sign-up to receive the latest news and ratings for JAGX and its competitors with MarketBeat's FREE daily newsletter. Jaguar Health (NASDAQ:JAGX) Frequently Asked Questions How has Jaguar Health's stock been impacted by COVID-19 (Coronavirus)? Jaguar Health's stock was trading at $0.45 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, JAGX stock has decreased by 1.7% and is now trading at $0.4424. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Jaguar Health? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jaguar Health in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Jaguar Health. When is Jaguar Health's next earnings date? Jaguar Health is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Jaguar Health. How were Jaguar Health's earnings last quarter? Jaguar Health Inc (NASDAQ:JAGX) issued its quarterly earnings data on Friday, May, 15th. The biotechnology company reported ($0.56) earnings per share for the quarter. The biotechnology company had revenue of $0.87 million for the quarter. Jaguar Health had a negative return on equity of 538.90% and a negative net margin of 755.26%. View Jaguar Health's earnings history. What price target have analysts set for JAGX? 2 brokerages have issued 12-month target prices for Jaguar Health's stock. Their forecasts range from $3.00 to $5.00. On average, they expect Jaguar Health's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 804.2% from the stock's current price. View analysts' price targets for Jaguar Health. Has Jaguar Health been receiving favorable news coverage? Headlines about JAGX stock have been trending very negative this week, according to InfoTrie Sentiment. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Jaguar Health earned a news impact score of -3.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutJaguar Health. Who are some of Jaguar Health's key competitors? Some companies that are related to Jaguar Health include AcelRx Pharmaceuticals (ACRX), Leap Therapeutics (LPTX), Corvus Pharmaceuticals (CRVS), CannTrust (CTST), Genprex (GNPX), Catalyst Biosciences (CBIO), Aptorum Group (APM), Clearside Biomedical (CLSD), Onconova Therapeutics (ONTX), Oncolytics Biotech (ONCY), Sesen Bio (SESN), Milestone Pharmaceuticals (MIST), CV Sciences (CVSI), Bellerophon Therapeutics (BLPH) and Otonomy (OTIC). View all competitors. What other stocks do shareholders of Jaguar Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Biopharmx (BPMX), Conatus Pharmaceuticals (CNAT), Cara Therapeutics (CARA), Precipio (PRPO), Neovasc (NVCN), PTC Therapeutics (PTCT), Achieve Life Sciences (ACHV), Cascadian Therapeutics (CASC), Cellectar Biosciences (CLRB) and Novavax (NVAX). Who are Jaguar Health's key executives? Jaguar Health's management team includes the following people: Ms. Lisa A. Conte, Founder, CEO, Pres & Director (Age 60)Ms. Karen S. Wright, CFO & Treasurer (Age 63)Dr. Steven R. King, Exec. VP of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec. (Age 61)Dr. Pravin R. Chaturvedi, Chair of Scientific Advisory Board & Acting Chief Scientific Officer (Age 56)Mr. Jonathan S. Wolin, Chief Compliance Officer & Corp. Counsel When did Jaguar Health IPO? (JAGX) raised $22 million in an initial public offering (IPO) on Wednesday, May 13th 2015. The company issued 3,200,000 shares at $7.00 per share. Aegis Capital Corp served as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers. What is Jaguar Health's stock symbol? Jaguar Health trades on the NASDAQ under the ticker symbol "JAGX." Who are Jaguar Health's major shareholders? Jaguar Health's stock is owned by many different retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (0.16%). Company insiders that own Jaguar Health stock include James J Bochnowski, Jonathan B Siegel, Lisa A Conte and Nantucket Investments Ltd. View institutional ownership trends for Jaguar Health. Which institutional investors are buying Jaguar Health stock? JAGX stock was acquired by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have bought Jaguar Health stock in the last two years include James J Bochnowski, Jonathan B Siegel, and Lisa A Conte. View insider buying and selling activity for Jaguar Health. How do I buy shares of Jaguar Health? Shares of JAGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Jaguar Health's stock price today? One share of JAGX stock can currently be purchased for approximately $0.44. How big of a company is Jaguar Health? Jaguar Health has a market capitalization of $26.02 million and generates $5.78 million in revenue each year. The biotechnology company earns $-38,540,000.00 in net income (profit) each year or ($6.89) on an earnings per share basis. Jaguar Health employs 40 workers across the globe. What is Jaguar Health's official website? The official website for Jaguar Health is www.jaguaranimalhealth.com. How can I contact Jaguar Health? Jaguar Health's mailing address is 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105. The biotechnology company can be reached via phone at 415-371-8300. This page was last updated on 6/4/2020 by MarketBeat.com Staff
